BRIEF COMMUNICATION Somatostatin receptor targeted radiopeptide therapy with yttrium-90-DOTATOC and lutetium-177-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial

DOTATOC in meningioma Abstract: 150 words Text: 2258 words, 2 tables, 4 figures, 20 references

[1]  W. Willinek,et al.  Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate , 2014, The Journal of Nuclear Medicine.

[2]  C. Rochlitz,et al.  Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  C. Rochlitz,et al.  Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study , 2013, Journal of Translational Medicine.

[4]  E. Krenning,et al.  Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions , 2012, The Journal of Nuclear Medicine.

[5]  C. Rochlitz,et al.  Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  E. Claus,et al.  Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. , 2011, Journal of neurosurgery.

[7]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  I. Shimon,et al.  Peptide receptor radioligand therapy is an effective treatment for the long‐term stabilization of malignant gastrinomas , 2011, Cancer.

[9]  Joseph Wiemels,et al.  Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.

[10]  C. Rochlitz,et al.  [90Yttrium‐DOTA]‐TOC response is associated with survival benefit in iodine‐refractory thyroid cancer , 2009, Cancer.

[11]  M. Cremonesi,et al.  Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Rochlitz,et al.  Response to [90Yttrium-DOTA]-TOC Treatment is Associated with Long-term Survival Benefit in Metastasized Medullary Thyroid Cancer: A Phase II Clinical Trial , 2007, Clinical Cancer Research.

[14]  R. Valkema,et al.  Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M. Béhé,et al.  DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy , 1997, European Journal of Nuclear Medicine.

[16]  E. Nitzsche,et al.  Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  R. Herrmann,et al.  Yttrium-90 DOTATOC: first clinical results , 1999, European Journal of Nuclear Medicine.

[18]  G. Beck,et al.  The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease , 1994 .

[19]  M G Stabin,et al.  Absorbed fractions for electrons and beta particles in spheres of various sizes. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  J. Foekens,et al.  High incidence of somatostatin receptors in human meningiomas: biochemical characterization. , 1986, The Journal of clinical endocrinology and metabolism.